Phase 3 Single Arm, Open Study on vYF in Adults

A Phase 3, Single Arm, Open Study to Assess the Immunogenicity and Safety of vYF in Adults Aged 18 Years and Over

The purpose of this study is to assess the safety and immunogenicity of vYF in adults aged 18 years and over in Japan.

Study details include:

• The study duration will be up to approximately 1 month.
• One single dose of vYF will be administrated subcutaneously at the 1st visit.
• The visit frequency will be Day 01 (Visit 01) and Day 29 (Visit 02). One telephone call (TC) will be planned at Day 15.

Number of Participants:

A total of 254 participants is expected to be included in the study with the aim to obtain a total of 203 evaluable participants.

Study Arms and Duration:

Eligible participants will receive, subcutaneously, a single dose of vYF vaccine on Day 1.

The duration of each participation will be approximately 1 month for each participant.

Study Overview

• Status: Completed
• Conditions: Yellow Fever
• Intervention / Treatment: Biological: Yellow fever vaccine (live)

Detailed Description

Duration of study participation: approximately 1 month for each participant

• Study Type: Interventional
• Enrollment (Actual): 254
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Osaka
    • Takatsuki, Osaka, Japan, 569-1192
      • Investigational Site Number : 3920001
  • Tokyo
    • Chūō, Tokyo, Japan, 103-0025
      • Investigational Site Number : 3920002
    • Shinjuku-ku, Tokyo, Japan, 169-0072
      • Investigational Site Number : 3920003
    • Taitō City, Tokyo, Japan, 111-0036
      • Investigational Site Number : 3920004

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Aged from 18 years on the day of inclusion*

  * "From 18 years" means from the day of the 18th birthday

• Participants who are healthy as determined by medical evaluation including medical history and physical examination.
• Able to attend all scheduled visits and to comply with all study procedures

• A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

  • Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile.

OR

. Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration.

A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) before any dose of study intervention on Day 01 and will be repeated on Day 29 to confirm the participant is still not pregnant within the 28 days of vaccine administration.

- Informed consent form (ICF) has been signed and dated Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy, or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
• Known history or laboratory evidence of HIV infection.
• Known history of hepatitis B or hepatitis C seropositivity
• Known history of FV infection, Japanese encephalitis (JE) excluded
• Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances
• Personal or family history of thymic pathology (thymoma, thymectomy, or myasthenia).

• Chronic illness* that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion, including malignancy, such as leukemia, or lymphoma

  * Chronic illness may include, but is not limited to cardiac disorders, renal disorders, auto-immune disorders, diabetes, psychiatric disorders or chronic infection

• Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 37.5°C [or ≥ 99.5°F]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
• Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion.
• Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following the study vaccination (prior to Visit 2 on Day 29), except for influenza vaccination, which may be received at least 2 weeks before study vaccines. This exception includes pandemic influenza vaccines including monovalent pandemic influenza vaccines.
• Previous vaccination against YF.
• Receipt of immune globulins, blood, or blood-derived products in the past 6 months.
• Administration of any anti-viral within 2 months preceding the vaccination and up to the 6 weeks following the vaccination.
• Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the course of the study in another clinical study investigating a vaccine, drug, medical device, or medical procedure.
• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
• Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
• Planned travel in a YF endemic country within 28 days of investigational vaccine administration.
• For participants greater than 60 years at the time of enrolment: any underlying medical condition (eg, cardiovascular disorders, organ failure) which could increase risk of a serious viscerotropic event or serious neurologic events.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: vYF; One single dose of vYF will be administered subcutaneously at the 1st visit	Biological: Yellow fever vaccine (live); Pharmaceutical form:Powder and diluent for suspension for injection-Route of administration:Subcutaneous; Other Names: vYF vaccine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of participants with seroconversion to YF virus in YF-naive participants	Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in neutralizing Ab (NAb) titers as compared to the pre-vaccination value (Day 01)	28 days after one dose of vYF vaccine

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with immediate adverse events	Immediate adverse events are any unsolicited systemic adverse events reported in the 30 minutes after vaccination	Within 30 minutes after vaccination
Percentage of participants with seroprotection to YF virus	Seroprotection is defined as NAb titers ≥ 10 (1/dil) at the corresponding timepoint	At Day 01 and Day 29
Percentage of participants with seroconversion to YF virus	Seroconversion rates will be assessed using a YF MN assay Seroconversion is defined as a 4-fold increase in neutralizing Ab (NAb) titers as compared to the pre-vaccination value (Day 01)	28 days after one dose of vYF vaccine
Geometric Mean Titers (GMTs) of neutralizing antibodies against YF virus	Antibody titers are expressed as GMTs	At Day 01 and Day 29
Geometric Mean Titers Ratio (GMTRs) of neutralizing antibodies against YF virus	GMTRs Day 29/Day 01	At Day 01 and Day 29
Number of participants with solicited injection site reactions	Solicited injection site reactions: injection site pain, injection site erythema, injection site swelling	Within 7 days after vaccination
Number of participants with solicited systemic reactions	Solicited systemic reactions: fever, headache, fatigue, myalgia	Within 14 days after vaccination
Number of participants with unsolicited adverse events (AEs), including adverse events of special interest (AESIs)	Unsolicited (spontaneously reported) AEs, not fulfilling criteria for solicited adverse reactions, including AESIs	Within 28 days after vaccination
Number of participants with serious adverse events (SAEs) including serious AESIs	SAEs including serious AESIs	Within 28 days after vaccination
Number of participants with related SAEs and all deaths	Related SAEs and all deaths	From Day 01 to Day 29 after vaccination

Collaborators and Investigators

• Sponsor: Sanofi Pasteur, a Sanofi Company

Publications and helpful links

Helpful Links

• VYF00011 Plain Language Results Summary

Study record dates

Study Major Dates

• Study Start (Actual): October 23, 2025
• Primary Completion (Actual): December 25, 2025
• Study Completion (Actual): December 25, 2025

Study Registration Dates

• First Submitted: October 27, 2025
• First Submitted That Met QC Criteria: October 27, 2025
• First Posted (Actual): October 29, 2025

Study Record Updates

• Last Update Posted (Actual): February 3, 2026
• Last Update Submitted That Met QC Criteria: February 2, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vector Borne Diseases; Mosquito-Borne Diseases; Infections; RNA Virus Infections; Virus Diseases; Arbovirus Infections; Flavivirus Infections; Flaviviridae Infections; Hemorrhagic Fevers, Viral; Yellow Fever; Biological Products; Complex Mixtures; Vaccines; Viral Vaccines; Yellow Fever Vaccine
• Other Study ID Numbers: VYF00011 (Other Identifier: Sanofi Identifier)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No